国际标准期刊å·: 2161-0460

阿尔茨海默病和帕金森病æ‚å¿—

开放获å–

我们集团组织了 3000 多个全çƒç³»åˆ—会议 æ¯å¹´åœ¨ç¾Žå›½ã€æ¬§æ´²å’Œç¾Žå›½ä¸¾åŠžçš„活动亚洲得到 1000 多个科学åä¼šçš„æ”¯æŒ å¹¶å‡ºç‰ˆäº† 700+ 开放获å–期刊包å«è¶…过50000å知å人士ã€çŸ¥å科学家担任编委会æˆå‘˜ã€‚

开放获å–期刊获得更多读者和引用
700 ç§æœŸåˆŠ å’Œ 15,000,000 å读者 æ¯ä»½æœŸåˆŠ 获得 25,000 多å读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • å¤å°”å·´·ç½—密欧
  • 打开 J é—¨
  • Genamics 期刊æœç´¢
  • 学术钥匙
  • 期刊目录
  • 中国知网(CNKI)
  • 电å­æœŸåˆŠå›¾ä¹¦é¦†
  • å‚考æœç´¢
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒å§
  • ICMJE
分享此页é¢

抽象的

Dietary Polyphenols as Potential Therapeutics in Alzheimer?s Disease: Pleiotropic Effects and Toxicity Prediction Models

Efstathia Kalli, Vlamos Panayiotis

Individualized nutritional treatment with polyphenols has been proposed in the early stages of Alzheimer’s disease. However, it remains unclear at what doses polyphenols and their metabolites enter the brain tissue and whether they can act at sufficient concentrations. The present review provides useful insights into the multiple modes of actions of selected polyphenols as potential therapeutic tools at the pre-clinical stage of Alzheimer’s disease, as well as their ability to cross the blood-brain barrier and their detrimental effects after high dose consumptions. Several studies proposed flavonoids for their potential value in prevention and treatment of neurodegenerative diseases. The scarcity of clinical data though highlights the need for conducting metabolomics studies and well-designed clinical trials. Prolonged clinical trials with bioinformatics tools are needed to fully elucidate both neuroprotective effects and possible risks from polyphenol consumption at concentrated high doses.

å…责声明: 此摘è¦é€šè¿‡äººå·¥æ™ºèƒ½å·¥å…·ç¿»è¯‘,尚未ç»è¿‡å®¡æ ¸æˆ–验è¯ã€‚